分類: 技術轉移招商

Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (2022/01/03)

1. Title: NHRI technology, “An Aurora kinase inhibitor for precision targeting of MYC-amplified cancers” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “Opioid Receptor Allosteric Modifier: DBPR116” (2021/1/28)

{:en} Title: NHRI technology, “Opioid Receptor Allosteric Modifier: DBPR116” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: The Technology relates to …

閱讀更多 →
技術轉移招商en文章

NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” available for technology licensing (exclusive license), 2020/08/17

Subject NHRI technology, “Induction of Stem Cell-derived Exosomes for Disease Treatment” (abbreviated as “The Technology”) available for technology licensing (exclusive license). Description The Technology is …

閱讀更多 →
技術轉移招商en文章

Technology Available for Technology Licensing. “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine(Jul 20,2020)

1.Title “Method and composition for decreasing the psychotomimetic side effect and addictive disorder of ketamine” (abbreviated as “The Technology”) available for technology licensing. 2.Description: The …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed …

閱讀更多 →